Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
Sponsor: Fudan University
Summary
The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.
Official title: Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment- a Prospective, Randomized, Single-blind, Controlled, Single-center, Head-to-head Clinical Cohort Study
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-08-19
Completion Date
2026-10-30
Last Updated
2026-07-17
Healthy Volunteers
No
Interventions
Canagliflozin group
Canagliflozin,100mg once daily, orally, for 6 months
Sitagliptin
Sitagliptin,100mg once daily, orally, for 6 months
Acarbose
Acarbose,100mg three times daily, orally, for 6 months
Locations (1)
Fudan University affiliated Huadong Hospital
Shanghai, Shanghai Municipality, China